









Markets
/
Stocks
/
nasdaq-bdtx
/

Black Diamond Therapeutics Inc

BDTX

3.280USD

-0.070-2.09%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

186.59MMarket Cap

12.92P/E TTM



Black Diamond Therapeutics Inc

3.280

-0.070-2.09%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

12 / 506

Overall Ranking

81 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 6 analysts

Strong Buy

Current Rating

9.800

Target Price

+192.54%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company focused on the development of MasterKey therapies that address families of oncogenic mutations in clinically validated targets. The Company’s MasterKey therapies are designed to address broad genetically defined patient populations, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system (CNS) disease. The Company is advancing two clinical-stage programs: BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR mutant non-small cell lung cancer (NSCLC) and glioblastoma (GBM), and BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS and BRAF alterations in solid tumors. Its BDTX-4876 is a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4. The Company is also focused on a development candidate against an undisclosed, validated oncogene.

Overvalued

The company’s latest PE is 12.75, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 48.09M shares, decreasing 36.00% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 2.10M shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 9.22, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is high.

Score

Industry at a Glance

Previous score

9.22

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.27

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.82

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 3.14, which is higher than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is 13.02, which is -106.01% below the recent high of -0.78 and 115.22% above the recent low of -1.98.

Score

Industry at a Glance

Previous score

3.14

Change

0.04

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 12/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 9.00, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Black Diamond Therapeutics Inc is 10.00, with a high of 11.00 and a low of 8.00.

Score

Industry at a Glance

Previous score

9.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 6 analysts

Strong Buy

Current Rating

9.800

Target Price

+192.54%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Black Diamond Therapeutics Inc

BDTX

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 9.06, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 3.67 and the support level at 2.80, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.06

Change

-0.3

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.040

Buy

RSI(14)

61.441

Neutral

STOCH(KDJ)(9,3,3)

70.752

Neutral

ATR(14)

0.181

High Vlolatility

CCI(14)

63.299

Neutral

Williams %R

20.270

Buy

TRIX(12,20)

0.761

Sell

StochRSI(14)

40.682

Sell

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

3.230

Buy

MA10

3.228

Buy

MA20

3.046

Buy

MA50

2.906

Buy

MA100

2.550

Buy

MA200

2.292

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 84.57%, representing a quarter-over-quarter decrease of 4.70%. The largest institutional shareholder is The Vanguard, holding a total of 2.10M shares, representing 3.69% of shares outstanding, with 13.42% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

T. Rowe Price Investment Management, Inc.

10.40M

-0.64%

Versant Ventures

6.21M

-3.45%

Vestal Point Capital, LP

5.60M

New Enterprise Associates (NEA)

4.45M

Bellevue Asset Management AG

2.73M

-67.91%

The Vanguard Group, Inc.

Star Investors

2.36M

-2.37%

Tang Capital Management, LLC

2.07M

Invus Public Equities Advisors, LLC

1.05M

Millennium Management LLC

1.10M

+97.81%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.10, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 3.03. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.